Profile picture

Doctor Essra Ridha

Bristol-Myers Squibb Pharmaceuticals Limited , London (United Kingdom of Great Britain & Northern Ireland)
Follow
Logo ESC

Contributor content

Are your atrial fibrillation (AF) patients protected from ischaemic stroke? Clinical characteristics of AF patients eligible for stroke prevention but remaining untreated in UK clinical practice
Presentation
Are your atrial fibrillation (AF) patients protected from ischaemic stroke? Clinical characteristics of AF patients eligible for stroke prevention but remaining untreated in UK clinical practice
Read more
Is Aspirin monotherapy effective for stroke prevention in the real world? A UK cohort study evaluating the incidence of stroke in the absence of anticoagulation in atrial fibrillation (AF)
Presentation
Is Aspirin monotherapy effective for stroke prevention in the real world? A UK cohort study evaluating the incidence of stroke in the absence of anticoagulation in atrial fibrillation (AF)
Read more
Aspirin, not without bleeding risk in the real world: results of a UK cohort study evaluating the use of antiplatelet therapy for stroke prevention in atrial fibrillation (AF)
Presentation
Aspirin, not without bleeding risk in the real world: results of a UK cohort study evaluating the use of antiplatelet therapy for stroke prevention in atrial fibrillation (AF)
Read more

ESC 365 is supported by

novartis Explore sponsored resources